Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
View ORCID ProfileUsman Arshad, Henry Pertinez, Helen Box, Lee Tatham, View ORCID ProfileRajith KR Rajoli, View ORCID ProfilePaul Curley, View ORCID ProfileMegan Neary, Joanne Sharp, View ORCID ProfileNeill J Liptrott, Anthony Valentijn, Christopher David, View ORCID ProfileSteve P Rannard, Paul O’Neill, View ORCID ProfileGhaith Aljayyoussi, View ORCID ProfileShaun Pennington, Stephen A Ward, David J Back, View ORCID ProfileSaye H Khoo, Patrick G Bray, View ORCID ProfileGiancarlo Biagini, View ORCID ProfileAndrew Owen
doi: https://doi.org/10.1101/2020.04.16.20068379
Usman Arshad
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Henry Pertinez
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Helen Box
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Lee Tatham
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Rajith KR Rajoli
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Paul Curley
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Megan Neary
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Joanne Sharp
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Neill J Liptrott
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Anthony Valentijn
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Christopher David
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Steve P Rannard
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
Paul O’Neill
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
Ghaith Aljayyoussi
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
Shaun Pennington
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
Stephen A Ward
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
David J Back
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Saye H Khoo
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Patrick G Bray
4Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK
Giancarlo Biagini
3Centre for Drugs and Diagnostics. Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
Andrew Owen
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L7 3NY, UK
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Posted April 22, 2020.
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith KR Rajoli, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Paul O’Neill, Ghaith Aljayyoussi, Shaun Pennington, Stephen A Ward, David J Back, Saye H Khoo, Patrick G Bray, Giancarlo Biagini, Andrew Owen
medRxiv 2020.04.16.20068379; doi: https://doi.org/10.1101/2020.04.16.20068379
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith KR Rajoli, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Paul O’Neill, Ghaith Aljayyoussi, Shaun Pennington, Stephen A Ward, David J Back, Saye H Khoo, Patrick G Bray, Giancarlo Biagini, Andrew Owen
medRxiv 2020.04.16.20068379; doi: https://doi.org/10.1101/2020.04.16.20068379
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2257)
- Dermatology (201)
- Emergency Medicine (368)
- Epidemiology (11549)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3541)
- Geriatric Medicine (336)
- Health Economics (612)
- Health Informatics (2287)
- Health Policy (910)
- Hematology (333)
- HIV/AIDS (742)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3326)
- Nursing (190)
- Nutrition (504)
- Oncology (1748)
- Ophthalmology (522)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (222)
- Palliative Medicine (66)
- Pathology (435)
- Pediatrics (998)
- Primary Care Research (399)
- Public and Global Health (5974)
- Radiology and Imaging (1216)
- Respiratory Medicine (807)
- Rheumatology (367)
- Sports Medicine (311)
- Surgery (383)
- Toxicology (50)
- Transplantation (170)
- Urology (142)